Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11710261 | 1.00 | TP53 (0.47) | TP53ACE2GPR84FDPSFFAR1 | |
| SCHEMBL1573362 | 0.83 | HDAC1 (0.37) | TP53FDPSCA1CA2 | |
| SCHEMBL27360543 | 0.78 | TP53 (0.42) | TP53ACE2GPR84FDPSFFAR1 | |
| SCHEMBL27800066 | 0.78 | TP53 (0.42) | TP53ACE2GPR84FDPSFFAR1 | |
| Sulfuric Acid SCHEMBL19811275 | 0.78 | TP53 (0.53) | TP53GPR84FDPSFFAR1LMNA | |
| Sulfuric Acid SCHEMBL19811354 | 0.78 | TP53 (0.53) | TP53GPR84FDPSFFAR1LMNA | |
| Sulfuric Acid SCHEMBL19811325 | 0.78 | TP53 (0.53) | TP53GPR84FDPSFFAR1LMNA | |
| Sulfuric Acid SCHEMBL19811663 | 0.78 | TP53 (0.53) | TP53GPR84FDPSFFAR1LMNA | |
| Sulfuric Acid SCHEMBL19811181 | 0.78 | TP53 (0.53) | TP53GPR84FDPSFFAR1LMNA | |
| Sulfuric Acid SCHEMBL19812222 | 0.78 | TP53 (0.53) | TP53GPR84FDPSFFAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100167323-A1 | stabilizing one or more analytes in solutions for a denaturing immunoassay of body samples; solubilizing, denaturing, heating, stabilizing and storing; human papilloma virus | VENTANA MEDICAL SYSTEMS, INC. | 2010-07-01 | — | — | US | claimed |
| US-20070184505-A1 | Method for stabilization of proteins in solution | VENTANA MEDICAL SYSTEMS, INC. | 2007-08-09 | — | — | US | claimed |
| EP-1816460-A1 | Method for stabilization of proteins in solution | MTM Laboratories AG (DE) | 2007-08-08 | — | — | EP | claimed |
| US-20060068390-A1 | Dna amplification and sequencing in collapsible emulsions | NUCLEICS PTY LTD. (AU) | 2006-03-30 | — | — | US | claimed |
| US-20230250492-A1 | Novel Cell Based Assay | Medical Diagnostics Laboratories, LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11319601-B2 | Cell based assay | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3199548-B1 | CERVIAL CANCER-RELATED HPV E7 PROTEIN MONOCLONAL ANTIBODY AND USE THEREOF | ATTOGEN BIOMEDICAL SUZHOU INC LTD (CN) | 2020-11-04 | — | — | EP | disclosed |
| US-10697966-B2 | Method for detecting cervical dysplasia | VENTANA MEDICAL SYSTEMS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200190592-A1 | PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION | Medical Diagnostic Laboratories, L.L.C. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-2885429-B1 | DIAGNOSTIC MARKERS OF INDOLENT PROSTATE CANCER | UNIV COLUMBIA (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10208357-B2 | Cell based assay | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-10167472-B2 | PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition | MEDICAL DIAGNOSTIC LABORATORIES, LLC (US) | 2019-01-01 | — | — | US | disclosed |
| WO-2004084866-A1 | METHOD FOR COATING DRUG-CONTAINING PARTICLES AND FORMULATIONS AND DOSAGE UNITS FORMED THEREFROM | TEDOR PHARMA, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040185170-A1 | Method for coating drug-containing particles and formulations and dosage units formed therefrom | TEDOR PHARMA, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040180388-A1 | Method for detecting carcinomas in a solubilized cervical body sample | VENTANA MEDICAL SYSTEMS, INC. | 2004-09-16 | — | — | US | disclosed |
| EP-1388734-B1 | Method for solution based diagnosis | MTM LAB AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2004013632-A1 | METHOD FOR SOLUTION BASED DIAGNOSIS | MTM LABORATORIES AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| EP-1388734-A1 | Method for solution based diagnosis | MTM Laboratories AG (DE) | 2004-02-11 | — | — | EP | disclosed |
| US-20040023288-A1 | Method for solution based diagnosis | VENTANA MEDICAL SYSTEMS, INC. | 2004-02-05 | — | — | US | disclosed |
| US-20020161323-A1 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT INC. | 2002-10-31 | — | — | US | disclosed |